1. Home
  2. TENX vs MCHX Comparison

TENX vs MCHX Comparison

Compare TENX & MCHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$1.83

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Logo Marchex Inc. Class B

MCHX

Marchex Inc. Class B

N/A

Current Price

$1.31

Market Cap

67.3M

ML Signal

N/A

Company Overview

Basic Information
Metric
TENX
MCHX
Founded
1967
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Business Services
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
71.1M
67.3M
IPO Year
2001
2003

Fundamental Metrics

Financial Performance
Metric
TENX
MCHX
Price
$1.83
$1.31
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $29.67
N/A
AVG Volume (30 Days)
★ 3.9M
40.3K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ N/A
Revenue
N/A
★ $90,291,000.00
Revenue This Year
N/A
$5.37
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$1.31
$1.15
52 Week High
$19.40
$2.04

Technical Indicators

Market Signals
Indicator
TENX
MCHX
Relative Strength Index (RSI) 27.10 35.39
Support Level $1.31 $1.15
Resistance Level $2.22 $1.73
Average True Range (ATR) 0.12 0.15
MACD 0.32 -0.01
Stochastic Oscillator 5.95 24.62

Price Performance

Historical Comparison
TENX
MCHX

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

About MCHX Marchex Inc. Class B

Marchex Inc provides AI-based conversational intelligence and analytics solutions that generate insights from customer communications data. The company's products support sales, marketing, and executive teams in analyzing customer interactions across communication channels and informing business decisions. It serves companies operating in business-to-business-to-consumer (B2B2C) markets across multiple industries like automotive, home services, healthcare, real estate, and advertising. The company operates in a single segment: conversational analytics and related solutions. The company generates the majority of revenue from its conversational intelligence product offerings. Geographically, it generates the maximum revenue from the United States.

Share on Social Networks: